JP2012006932A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012006932A5 JP2012006932A5 JP2011155493A JP2011155493A JP2012006932A5 JP 2012006932 A5 JP2012006932 A5 JP 2012006932A5 JP 2011155493 A JP2011155493 A JP 2011155493A JP 2011155493 A JP2011155493 A JP 2011155493A JP 2012006932 A5 JP2012006932 A5 JP 2012006932A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- pharmaceutical composition
- composition according
- integrin
- expresses
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims 4
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims 4
- 102000006495 integrins Human genes 0.000 claims 4
- 108010044426 integrins Proteins 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 150000002895 organic esters Chemical class 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 229920005862 polyol Polymers 0.000 claims 2
- 150000003077 polyols Chemical class 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 2
- 239000008158 vegetable oil Substances 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims 1
- 229940093471 ethyl oleate Drugs 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000008297 liquid dosage form Substances 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000010807 negative regulation of binding Effects 0.000 claims 1
- 235000008390 olive oil Nutrition 0.000 claims 1
- 239000004006 olive oil Substances 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13296799P | 1999-05-07 | 1999-05-07 | |
| US60/132,967 | 1999-05-07 | ||
| US17044199P | 1999-12-10 | 1999-12-10 | |
| US60/170,441 | 1999-12-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000617169A Division JP4841729B2 (ja) | 1999-05-07 | 2000-05-05 | インテグリンのその受容体への結合を阻害するプロパン酸誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012006932A JP2012006932A (ja) | 2012-01-12 |
| JP2012006932A5 true JP2012006932A5 (https=) | 2012-09-20 |
| JP5468578B2 JP5468578B2 (ja) | 2014-04-09 |
Family
ID=26830910
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000617169A Expired - Fee Related JP4841729B2 (ja) | 1999-05-07 | 2000-05-05 | インテグリンのその受容体への結合を阻害するプロパン酸誘導体 |
| JP2011155493A Expired - Fee Related JP5468578B2 (ja) | 1999-05-07 | 2011-07-14 | インテグリンのその受容体への結合を阻害するプロパン酸誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000617169A Expired - Fee Related JP4841729B2 (ja) | 1999-05-07 | 2000-05-05 | インテグリンのその受容体への結合を阻害するプロパン酸誘導体 |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1189881B2 (https=) |
| JP (2) | JP4841729B2 (https=) |
| KR (1) | KR100767199B1 (https=) |
| CN (1) | CN100360499C (https=) |
| AT (1) | ATE277923T1 (https=) |
| AU (1) | AU4826900A (https=) |
| BR (1) | BR0010349B1 (https=) |
| CA (1) | CA2373180C (https=) |
| CZ (1) | CZ304225B6 (https=) |
| DE (1) | DE60014369T3 (https=) |
| ES (1) | ES2228527T5 (https=) |
| HK (1) | HK1044533A1 (https=) |
| HU (1) | HU229155B1 (https=) |
| IL (2) | IL146312A0 (https=) |
| MX (1) | MXPA01011341A (https=) |
| NO (1) | NO329899B1 (https=) |
| NZ (1) | NZ515249A (https=) |
| RO (1) | RO121640B1 (https=) |
| RU (1) | RU2255933C9 (https=) |
| SI (1) | SI20876B (https=) |
| SK (1) | SK288186B6 (https=) |
| TR (1) | TR200103427T2 (https=) |
| WO (1) | WO2000068188A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| US6723711B2 (en) * | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| AR026748A1 (es) | 1999-12-08 | 2003-02-26 | Vertex Pharma | Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis |
| PE20020420A1 (es) | 2000-10-02 | 2002-06-27 | Novartis Ag | Derivados de diazacicloalcanodiona como antagonistas del antigeno asociado a la funcion del linfocito-1 (lfa-1) |
| FR2834212B1 (fr) * | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
| PL374598A1 (en) | 2002-06-28 | 2005-10-31 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| AU2003265398A1 (en) | 2002-08-09 | 2004-02-25 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds and methods to modulate coagulation |
| US7612091B2 (en) | 2002-12-20 | 2009-11-03 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| PE20050159A1 (es) | 2003-05-27 | 2005-04-19 | Vertex Pharma | Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa |
| US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| US7501538B2 (en) | 2003-08-08 | 2009-03-10 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
| US7544699B2 (en) | 2003-08-08 | 2009-06-09 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| EP1828144A2 (en) | 2004-11-12 | 2007-09-05 | OSI Pharmaceuticals, Inc. | Integrin antagonists useful as anticancer agents |
| ES2600460T3 (es) | 2005-05-10 | 2017-02-09 | Intermune, Inc. | Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés |
| KR20080031379A (ko) | 2005-07-11 | 2008-04-08 | 와이어쓰 | 글루타메이트 아그레카나제 저해제 |
| KR20080058436A (ko) | 2005-10-13 | 2008-06-25 | 와이어쓰 | 글루탐산 유도체의 제조 방법 |
| CN102099036B (zh) | 2008-06-03 | 2015-05-27 | 英特芒尼公司 | 用于治疗炎性疾患和纤维化疾患的化合物和方法 |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| US10875875B2 (en) * | 2017-04-26 | 2020-12-29 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
| EP3773573B1 (en) | 2018-04-12 | 2026-03-18 | Morphic Therapeutic, Inc. | Antagonists of human integrin (alpha4)(beta7) |
| TWI775182B (zh) | 2019-10-16 | 2022-08-21 | 美商莫菲克醫療股份有限公司 | 抑制人類整合素αβ |
| CN118354999A (zh) * | 2022-01-11 | 2024-07-16 | 深圳信立泰药业股份有限公司 | 一种哒嗪-1(6h)-6-氧代类化合物及其制备方法与应用 |
| WO2024235299A1 (zh) * | 2023-05-17 | 2024-11-21 | 西藏海思科制药有限公司 | 一种羧基衍生物及其在医药上的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874424A (en) * | 1995-12-20 | 1999-02-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| GR851819B (https=) * | 1984-08-17 | 1985-11-26 | Wyeth John & Brother Ltd | |
| WO1992019595A1 (en) * | 1991-05-07 | 1992-11-12 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| US5847135A (en) * | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
| EP0761680A3 (en) * | 1995-09-12 | 1999-05-06 | Ono Pharmaceutical Co., Ltd. | Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity |
| NZ333904A (en) * | 1996-07-25 | 2000-06-23 | Biogen Inc | VLA-4 and IIb/IIIa cell adhesion inhibitors |
| JP2002511052A (ja) * | 1996-08-29 | 2002-04-09 | メルク エンド カンパニー インコーポレーテッド | インテグリンアンタゴニスト |
| AU738341B2 (en) * | 1996-10-11 | 2001-09-13 | Abbott Gmbh & Co. Kg | Asparate ester inhibitors of interleukin-1beta converting enzyme |
| DE19647380A1 (de) * | 1996-11-15 | 1998-05-20 | Hoechst Ag | 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
| AR016751A1 (es) * | 1996-11-22 | 2001-08-01 | Athena Neurosciences Inc | Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo |
| NZ500620A (en) * | 1997-05-02 | 2000-10-27 | Akzo Nobel Nv | Synthetic peptides which inhibit serine proteases, specifically thrombin, factor VIIa tissue factor and factor Xa |
| DE19741235A1 (de) * | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| US6331640B1 (en) * | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
| WO2000061631A1 (en) * | 1999-04-12 | 2000-10-19 | Astrazeneca Ab | Modified pentapeptide antagonists of the atrial natriuretic peptide clearance receptor |
-
2000
- 2000-05-05 RU RU2001133341/04A patent/RU2255933C9/ru not_active IP Right Cessation
- 2000-05-05 AU AU48269/00A patent/AU4826900A/en not_active Abandoned
- 2000-05-05 AT AT00930450T patent/ATE277923T1/de not_active IP Right Cessation
- 2000-05-05 EP EP00930450A patent/EP1189881B2/en not_active Expired - Lifetime
- 2000-05-05 BR BRPI0010349-7A patent/BR0010349B1/pt not_active IP Right Cessation
- 2000-05-05 HU HU0202184A patent/HU229155B1/hu not_active IP Right Cessation
- 2000-05-05 SI SI200020020A patent/SI20876B/sl not_active IP Right Cessation
- 2000-05-05 CN CNB00809957XA patent/CN100360499C/zh not_active Expired - Fee Related
- 2000-05-05 WO PCT/US2000/012464 patent/WO2000068188A1/en not_active Ceased
- 2000-05-05 KR KR1020017014179A patent/KR100767199B1/ko not_active Expired - Fee Related
- 2000-05-05 DE DE60014369T patent/DE60014369T3/de not_active Expired - Lifetime
- 2000-05-05 IL IL14631200A patent/IL146312A0/xx unknown
- 2000-05-05 SK SK1609-2001A patent/SK288186B6/sk not_active IP Right Cessation
- 2000-05-05 RO ROA200101209A patent/RO121640B1/ro unknown
- 2000-05-05 NZ NZ515249A patent/NZ515249A/en not_active IP Right Cessation
- 2000-05-05 HK HK02106258.2A patent/HK1044533A1/zh unknown
- 2000-05-05 MX MXPA01011341A patent/MXPA01011341A/es active IP Right Grant
- 2000-05-05 CA CA002373180A patent/CA2373180C/en not_active Expired - Fee Related
- 2000-05-05 JP JP2000617169A patent/JP4841729B2/ja not_active Expired - Fee Related
- 2000-05-05 TR TR2001/03427T patent/TR200103427T2/xx unknown
- 2000-05-05 CZ CZ2001-3983A patent/CZ304225B6/cs not_active IP Right Cessation
- 2000-05-05 ES ES00930450T patent/ES2228527T5/es not_active Expired - Lifetime
-
2001
- 2001-11-01 IL IL146312A patent/IL146312A/en not_active IP Right Cessation
- 2001-11-06 NO NO20015419A patent/NO329899B1/no not_active IP Right Cessation
-
2011
- 2011-07-14 JP JP2011155493A patent/JP5468578B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012006932A5 (https=) | ||
| MX2021011472A (es) | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. | |
| Locatelli et al. | NF-κB1 deficiency stimulates the progression of non-alcoholic steatohepatitis (NASH) in mice by promoting NKT-cell-mediated responses | |
| CL2013003331A1 (es) | Tableta de liberacion inmediata a prueba de alteracion que comprende (i) una matriz, y (ii) una pluralidad de material particulado, que comprende un opiaceo y un polimero de oxido de polietileno de mas de 20.000 g/mol, donde el multiparticulado forma una fase discontinua dentro de la matriz. | |
| ES2752039T3 (es) | Agente terapéutico para la dislipidemia | |
| RU2017121277A (ru) | Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения | |
| JP2018505158A5 (https=) | ||
| JP2013533884A5 (https=) | ||
| MX374414B (es) | Nuevos agentes anti-inflamatorios. | |
| JP2010174019A5 (https=) | ||
| AR077638A1 (es) | Compuesto de (metanosulfonil -piperidin )-( alcoxi-aril) -tetrahidro- piridina , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de diabetes u obesidad | |
| JP2015503593A5 (https=) | ||
| JP2012504133A5 (https=) | ||
| AR075104A1 (es) | Compuesto de piperazin-aril-purina, su uso para preparar un medicamento util para el tratamiento del dolor y composicion farmaceutica que lo comprende | |
| CL2007003440A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida | |
| JP2017525718A5 (https=) | ||
| BR112012016460A2 (pt) | diazóxido ou um sal farmaceuticamente aceitável deste e método para sua utilização no tratamento de uma doença desmielinizante autoimune do sistema nervoso central (cns), e composição farmacêutica. | |
| HRP20161328T1 (hr) | Postupak i uređaj za razdvajanje karboksilnih kiselina i/ili estera karboksilne kiseline | |
| JP2013522316A5 (https=) | ||
| PH12014502609A1 (en) | Mutilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug | |
| JP2019516761A5 (https=) | ||
| JP2013513607A5 (https=) | ||
| EP2267543A3 (en) | Electrophotographic photoreceptor, image forming apparatus and process cartridge | |
| Manni et al. | Old and young actors playing novel roles in the drama of multiple myeloma bone marrow microenvironment dependent drug resistance | |
| WO2007097992A3 (en) | Novel heterocyclic diphenyl ethers |